Zobrazeno 1 - 10
of 28
pro vyhledávání: '"Marco Mirani"'
Autor:
Walter Vena, Stella Pigni, Nazarena Betella, Annalisa Navarra, Marco Mirani, Gherardo Mazziotti, Andrea G. Lania, Antonio C. Bossi
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 20, Iss 1 (2024)
Purpose To overview the recent literature regarding the relationship between COVID-19 vaccines and glycemic control.Methods Data were extracted from text and tables of all available articles published up to September 2023 in PubMed Database describin
Externí odkaz:
https://doaj.org/article/c9485f28c5c74086a8f46dd103ad702e
Autor:
Sara Piccini, Giuseppe Favacchio, Cristina Panico, Emanuela Morenghi, Franco Folli, Gherardo Mazziotti, Andrea Gerardo Lania, Marco Mirani
Publikováno v:
Cardiovascular Diabetology, Vol 22, Iss 1, Pp 1-14 (2023)
Abstract Background Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have shown cardiovascular benefits in cardiovascular outcome trials in type 2 diabetes mellitus. However, the most convincing evidence was obtained in subjects with established
Externí odkaz:
https://doaj.org/article/90dfb7662cc049948061b82984ee197b
Autor:
Cesare C. Berra, Maria Chiara Rossi, Marco Mirani, Daniela Ceccarelli Ceccarelli, Cristina Romano, Lorenza Sassi, Elena Peretti, Giuseppe Favacchio, Ida Pastore, Laura Folini, Giusi Graziano, Maria Elena Lunati, Sebastiano Bruno Solerte, Paolo Fiorina
Publikováno v:
Frontiers in Endocrinology, Vol 13 (2023)
IntroductionAim of the present study was to evaluate the real-world impact of once-weekly (OW) subcutaneous semaglutide on different end-points indicative of metabolic control, cardiovascular risk factors, and beta-cell function in type 2 diabetes (T
Externí odkaz:
https://doaj.org/article/4f611f2065d640518d2f4fd3fb976c0d
Autor:
Maria Elena Lunati, Vincenzo Cimino, Alessandra Gandolfi, Matteo Trevisan, Laura Montefusco, Ida Pastore, Camilla Pace, Nazarena Betella, Giuseppe Favacchio, Monica Bulgheroni, Loredana Bucciarelli, Giulia Massari, Cristina Mascardi, Angela Girelli, Paola Silvia Morpurgo, Franco Folli, Livio Luzi, Marco Mirani, Basilio Pintaudi, Federico Bertuzzi, Cesare Berra, Paolo Fiorina
Publikováno v:
Pharmacological Research, Vol 183, Iss , Pp 106396- (2022)
Background and aims: Sodium-glucose co-transporter-2 inhibitors (SGLT2i) may have important benefits for the elderly with type 2 diabetes (T2D), however some safety concerns still limit their use in patients over 70 years of age. The SOLD study (SGLT
Externí odkaz:
https://doaj.org/article/4a2c41cb4fed45eeadd7317aaca28290
Autor:
Cesare Celeste Berra, Roberto Manfrini, Marco Mirani, Loredana Bucciarelli, Amhed S Zakaria, Sara Piccini, Renata Ghelardi, Maria Elena Lunati, Sylka Rodovalho, Francesco Bifari, Paolo Fiorina, Franco Folli
Background Cardiovascular (CV) risk assessment may result unpractical in real-world clinical practice, although being considered a key step for choosing appropriate therapies for patients with Type 2 Diabetes Mellitus (T2DM). In order to streamline t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e6ff8028e93a496341728e56799aa60c
https://doi.org/10.21203/rs.3.rs-2134695/v2
https://doi.org/10.21203/rs.3.rs-2134695/v2
Autor:
Simone Antonini, Marco Mirani, Andrea Lania, Maria Francesca Birtolo, Giulia Maida, Gherardo Mazziotti
Publikováno v:
L'Endocrinologo
Sommario L’infezione da SARS-CoV-2 è rapidamente diventata una pandemia globale, con più di 100 milioni di persone infettate e 2,3 milioni di morti nel mondo. Particolare attenzione è stata posta all’influenza reciproca tra infezione da SARS-C
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e486ec2f29760f87d20101ae7b1c9c6c
https://doi.org/10.1007/s40619-021-00949-7
https://doi.org/10.1007/s40619-021-00949-7
Publikováno v:
Endocrine Abstracts.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8808a3911c44802bce27a8e2612f1ff5
https://doi.org/10.1530/endoabs.81.rc10.8
https://doi.org/10.1530/endoabs.81.rc10.8
Autor:
Marco Mirani, Riccardo Colombo, Ida Pastore, Rosalia Bellante, Francesca D'Addio, Angelo Corsico, Alessandro Roberto Dodesini, Cristiana Scaranna, Silvia Galliani, Sebastiano Bruno Solerte, Roberto Trevisan, Elisabetta Lovati, Giuseppe Lepore, Franco Folli, Emanuele Catena, Salvatore Endrio Oleandri, Marco Dell’Acqua, Antonio Rossi, Elio Ippolito, Francesca Geni, Antonio Di Sabatino, Carlo De Riva, Gian Vincenzo Zuccotti, Paolo Fiorina, Roberta Maria Fiorina, Reza Abdi, Massimo Galli, Joseph V. Bonventre, Stefano Rusconi
Publikováno v:
Diabetes Care
OBJECTIVE Poor outcomes have been reported in patients with type 2 diabetes and coronavirus disease 2019 (COVID-19); thus, it is mandatory to explore novel therapeutic approaches for this population. RESEARCH DESIGN AND METHODS In a multicenter, case
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::58470657effa028da010fea138830be2
http://europepmc.org/articles/PMC7770266
http://europepmc.org/articles/PMC7770266
Autor:
Mauro Gitto, Alexios S. Kotinas, Riccardo Terzi, Angelo Oliva, Jorgele Zagoreo, Bernhard Reimers, Giulio G. Stefanini, Marco Mirani, Giuseppe Favacchio, Gianluigi Condorelli, Cristina Panico
Publikováno v:
Journal of cardiovascular pharmacology. 80(1)
Despite large-scale randomized clinical trials (RCTs) highlighting a consistent prognostic benefit of sodium-glucose cotransporter 2 inhibitors (SGLT2is) both in diabetic patients at high cardiovascular risk and in those with heart failure, there is
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::66595d1dbe1da56fbd6620fa6fdce6e3
https://pubmed.ncbi.nlm.nih.gov/35436244
https://pubmed.ncbi.nlm.nih.gov/35436244
Autor:
Mauro Gitto, Alexios Kotinas, Riccardo Terzi, Angelo Oliva, Jorgele Zagoreo, Bernhard Reimers, Giulio G Stefanini, Marco Mirani, Giuseppe Favacchio, Gianluigi Condorelli, Cristina Panico
Publikováno v:
European Heart Journal Supplements. 23
Aims Sodium–glucose cotransporter 2 inhibitors (SGLT2i) have become a first-line cardiovascular medication. However, their potential side effects still limit a widespread use in real-world clinical practice. Further, there is uncertainty about the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5088da5195d319caf3a92246c5b803d9
https://doi.org/10.1093/eurheartj/suab136.003
https://doi.org/10.1093/eurheartj/suab136.003